These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34960645)

  • 1. Systemic Inflammation and Complement Activation Parameters Predict Clinical Outcome of Severe SARS-CoV-2 Infections.
    Huber S; Massri M; Grasse M; Fleischer V; Kellnerová S; Harpf V; Knabl L; Knabl L; Heiner T; Kummann M; Neurauter M; Rambach G; Speth C; Würzner R
    Viruses; 2021 Nov; 13(12):. PubMed ID: 34960645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement Activation in the Disease Course of Coronavirus Disease 2019 and Its Effects on Clinical Outcomes.
    de Nooijer AH; Grondman I; Janssen NAF; Netea MG; Willems L; van de Veerdonk FL; Giamarellos-Bourboulis EJ; Toonen EJM; Joosten LAB;
    J Infect Dis; 2021 Feb; 223(2):214-224. PubMed ID: 33038254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Escalated complement activation during hospitalization is associated with higher risk of 60-day mortality in SARS-CoV-2-infected patients.
    Barratt-Due A; Pettersen K; Børresdatter-Dahl T; Holter JC; Grønli RH; Dyrhol-Riise AM; Lerum TV; Holten AR; Tonby K; Trøseid M; Skjønsberg OH; Granerud BK; Heggelund L; Kildal AB; Schjalm C; Aaløkken TM; Aukrust P; Ueland T; Mollnes TE; Halvorsen B;
    J Intern Med; 2024 Jul; 296(1):80-92. PubMed ID: 38539241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement Overactivation and Consumption Predicts In-Hospital Mortality in SARS-CoV-2 Infection.
    Sinkovits G; Mező B; Réti M; Müller V; Iványi Z; Gál J; Gopcsa L; Reményi P; Szathmáry B; Lakatos B; Szlávik J; Bobek I; Prohászka ZZ; Förhécz Z; Csuka D; Hurler L; Kajdácsi E; Cervenak L; Kiszel P; Masszi T; Vályi-Nagy I; Prohászka Z
    Front Immunol; 2021; 12():663187. PubMed ID: 33841446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C5aR inhibition of nonimmune cells suppresses inflammation and maintains epithelial integrity in SARS-CoV-2-infected primary human airway epithelia.
    Posch W; Vosper J; Noureen A; Zaderer V; Witting C; Bertacchi G; Gstir R; Filipek PA; Bonn GK; Huber LA; Bellmann-Weiler R; Lass-Flörl C; Wilflingseder D
    J Allergy Clin Immunol; 2021 Jun; 147(6):2083-2097.e6. PubMed ID: 33852936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement cascade in severe forms of COVID-19: Recent advances in therapy.
    Chouaki Benmansour N; Carvelli J; Vivier E
    Eur J Immunol; 2021 Jul; 51(7):1652-1659. PubMed ID: 33738806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thromboinflammation Supports Complement Activation in Cancer Patients With COVID-19.
    Peerschke EI; Valentino A; So RJ; Shulman S; Ravinder
    Front Immunol; 2021; 12():716361. PubMed ID: 34491250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A disturbed balance between blood complement protective factors (FH, ApoE) and common pathway effectors (C5a, TCC) in acute COVID-19 and during convalesce.
    Laudanski K; Okeke T; Siddiq K; Hajj J; Restrepo M; Gullipalli D; Song WC
    Sci Rep; 2022 Aug; 12(1):13658. PubMed ID: 35953544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement C5a and Clinical Markers as Predictors of COVID-19 Disease Severity and Mortality in a Multi-Ethnic Population.
    Cyprian FS; Suleman M; Abdelhafez I; Doudin A; Masud Danjuma M; Mir FA; Parray A; Yousaf Z; Siddiqui MYA; Abdelmajid A; Mulhim M; Al-Shokri S; Abukhattab M; Shaheen R; Elkord E; Al-Khal AL; Elzouki AN; Girardi G
    Front Immunol; 2021; 12():707159. PubMed ID: 34966381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 Antibodies Mediate Complement and Cellular Driven Inflammation.
    Jarlhelt I; Nielsen SK; Jahn CXH; Hansen CB; Pérez-Alós L; Rosbjerg A; Bayarri-Olmos R; Skjoedt MO; Garred P
    Front Immunol; 2021; 12():767981. PubMed ID: 34804055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement and endothelial cell activation in COVID-19 patients compared to controls with suspected SARS-CoV-2 infection: A prospective cohort study.
    Bruni F; Charitos P; Lampart M; Moser S; Siegemund M; Bingisser R; Osswald S; Bassetti S; Twerenbold R; Trendelenburg M; Rentsch KM; Osthoff M
    Front Immunol; 2022; 13():941742. PubMed ID: 36203596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis.
    Gralinski LE; Sheahan TP; Morrison TE; Menachery VD; Jensen K; Leist SR; Whitmore A; Heise MT; Baric RS
    mBio; 2018 Oct; 9(5):. PubMed ID: 30301856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients.
    Holter JC; Pischke SE; de Boer E; Lind A; Jenum S; Holten AR; Tonby K; Barratt-Due A; Sokolova M; Schjalm C; Chaban V; Kolderup A; Tran T; Tollefsrud Gjølberg T; Skeie LG; Hesstvedt L; Ormåsen V; Fevang B; Austad C; Müller KE; Fladeby C; Holberg-Petersen M; Halvorsen B; Müller F; Aukrust P; Dudman S; Ueland T; Andersen JT; Lund-Johansen F; Heggelund L; Dyrhol-Riise AM; Mollnes TE
    Proc Natl Acad Sci U S A; 2020 Oct; 117(40):25018-25025. PubMed ID: 32943538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C5a elevation in convalescents from severe COVID-19 is not associated with early complement activation markers C3bBbP or C4d.
    Kowalska D; Kuźniewska A; Senent Y; Tavira B; Inogés S; López-Díaz de Cerio A; Pio R; Okrój M; Yuste JR
    Front Immunol; 2022; 13():946522. PubMed ID: 36091057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chromosome 3 cluster rs11385942 variant links complement activation with severe COVID-19.
    Valenti L; Griffini S; Lamorte G; Grovetti E; Uceda Renteria SC; Malvestiti F; Scudeller L; Bandera A; Peyvandi F; Prati D; Meroni P; Cugno M
    J Autoimmun; 2021 Feb; 117():102595. PubMed ID: 33453462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement activation predicts negative outcomes in COVID-19: The experience from Northen Italian patients.
    Meroni PL; Croci S; Lonati PA; Pregnolato F; Spaggiari L; Besutti G; Bonacini M; Ferrigno I; Rossi A; Hetland G; Hollan I; Cugno M; Tedesco F; Borghi MO; Salvarani C
    Autoimmun Rev; 2023 Jan; 22(1):103232. PubMed ID: 36414219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of Complement Components on Circulating Blood Monocytes From COVID-19 Patients.
    Lage SL; Rocco JM; Laidlaw E; Rupert A; Galindo F; Kellogg A; Kumar P; Poon R; Wortmann GW; Lisco A; Manion M; Sereti I
    Front Immunol; 2022; 13():815833. PubMed ID: 35250994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement Anaphylatoxins and Inflammatory Cytokines as Prognostic Markers for COVID-19 Severity and In-Hospital Mortality.
    Alosaimi B; Mubarak A; Hamed ME; Almutairi AZ; Alrashed AA; AlJuryyan A; Enani M; Alenzi FQ; Alturaiki W
    Front Immunol; 2021; 12():668725. PubMed ID: 34276659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Involvement of the complement cascade in severe forms of COVID-19].
    Chouaki Benmansour N; Carvelli J; Vivier É
    Med Sci (Paris); 2021 Apr; 37(4):333-341. PubMed ID: 33835019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune and inflammation features of severe and critical Omicron infected patients during Omicron wave in China.
    Liu Y; Guo Y; Zhan H; Liu X; Li X; Cui J; Li H; Feng S; Cheng L; Li X; Guo S; Li Y
    BMC Infect Dis; 2024 Aug; 24(1):809. PubMed ID: 39123106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.